Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholde...(rovided by (used in) financing act...),Health

activities from discontinued operations 292 (3,024)

Net cash provided by (used in) financing

activities 741 (1,902)

Net decrease in cash and cash equivalents (8,187) (69,742)

Cash and cash equivalents at beginning of

period 86,227 101,762

Cash and cash equivalents at end of period $78,040 $32,020

Nabi Biopharmaceuticals

SUPPLEMENTAL SEGMENT INFORMATION

(Unaudited)

For the Three Months For the Nine Months

Ended Ended

(In thousands) September 29, September 30, September 29, September 30,

2007 2006 2007 2006

Revenues:

Biologics SBU $20,075 $19,484 $64,689 $58,411

Pharmaceuticals

SBU 35 150 42 1,114

Total $20,110 $19,634 $64,731 $59,525

Gross margin (loss):

Biologics SBU $5,381 $4,170 $23,626 $14,776

Pharmaceuticals SBU 35 36 (76) 439

Total $5,416 $4,206 $23,550 $15,215

Operating loss:

Biologics SBU $(6,437) $(2,714) $(2,999) $(2,021)

Pharmaceuticals

SBU (2,160) (5,309) (9,895) (18,775)

Segment operating

loss (8,597) (8,023) (12,894) (20,796)

CSS (7,834) (8,377) (23,094) (25,255)

Total $(16,431) $(16,400) $(35,988) $(46,051)